Please wait while the formulary information is being retrieved.
INGREZZA (VALBENAZINE TOSYLATE)
- Tardive dyskinesia
40 mg capsule
- 2 capsules (80 mg) by oral route once daily
80 mg capsule
- 1 capsule (80 mg) by oral route once daily
Tardive dyskinesia
- 1 capsule (40 mg) by oral route once daily
- 2 capsules (80 mg) by oral route once daily
- 1 capsule (80 mg) by oral route once daily
- None
Contraindicated
- Hycamtin
- topotecan
Severe
Moderate
- afatinib
- Etopophos
- etoposide
- etoposide phosphate
- Gilotrif
- Toposar
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Congenital long QT syndrome
Contraindicated
- CYp2d6 poor metabolizer
- Disease of liver
- Parkinsonism
Severe
Moderate
- None
INGREZZA (VALBENAZINE TOSYLATE)
- Tardive dyskinesia
- None
- Drowsy
More Frequent
Severe
Less Severe
- Akathisia
- Parkinsonism
- Arthralgias
- Ataxia
- Blurred vision
- Constipation
- Disturbance of attention
- Dizziness
- Gait abnormality
- Headache disorder
- Nausea
- Nervousness
- Urinary retention
- Vomiting
- Xerostomia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Angioedema
- Dyskinesia
- Prolonged QT interval
Less Severe
- Allergic dermatitis
- Hyperbilirubinemia
- Hyperglycemia
- Hyperprolactinemia
- Insomnia
- Pruritus of skin
- Sialorrhea
- Skin rash
- Symptoms of anxiety
- Upper respiratory infection
- Urticaria
- Weight gain
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Valbenazine
No established safety and efficacy in pediatrics.
- 1 Day – 18 Years
- No established safety and efficacy in pediatrics.
Valbenazine
- Severity Level:
2
- Additional Notes: Insuff human data; animal data sug dev tox, consider mat ben vs. fetal risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Valbenazine
Insuff data avail; mfg does not rec during tx or for 5 days after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insuff data avail; mfg does not rec during tx or for 5 days after last dose |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Tardive dyskinesia | |
| G24.0 | Drug induced dystonia |
| G24.01 | Drug induced subacute dyskinesia |
| G24.09 | Other drug induced dystonia |
| 0-9 | A-Z |
|---|---|
| G24.0 | Drug induced dystonia |
| G24.01 | Drug induced subacute dyskinesia |
| G24.09 | Other drug induced dystonia |
Formulary Reference Tool